23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › AXSOME THERAPEUTICS INC. › 2023-2024

AXSOME THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and AXSOME THERAPEUTICS INC.’s Form 8-K, filed June 11, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 264Asset managers, any item
  • 1,154Fund votes
  • June 7, 2024Meeting date

Results at a glance

Meeting of June 7, 2024: 4 items on AXSOME THERAPEUTICS INC.’s Form 8-K, filed June 11, 2024: 2 elected · 2 approved.

Dissent

Notable dissent: 1 director (19.7% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore AXSOME THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by AXSOME THERAPEUTICS INC.

These tallies are AXSOME THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 11, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

AXSOME THERAPEUTICS INC. — official shareholder meeting results, meeting held June 7, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Herriot Tabuteau, M.D. 33,257,792---- 526,5456,137,450 98%Elected—
Elect Director: Mark Coleman, M.D. 27,121,859---- 6,662,4786,137,450 80%Elected—
2. Ratification of Appointment of Deloitte & Touche LLP 39,146,384153,117622,286 --0 99.6%Approved—
3. Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers 32,850,943866,04667,348 --6,137,450 97%Approved—

Source: AXSOME THERAPEUTICS INC., Form 8-K, filed with the SEC on June 11, 2024 — read the filing on EDGAR.

How asset managers voted at the AXSOME THERAPEUTICS INC. 2023-2024 meeting

264 asset managers disclosed a vote on at least one AXSOME THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Herriot Tabuteau, M.D.

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 33,257,792WITHHELD: 526,545
Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: Election of Directors: Herriot Tabuteau, M.D.

AXSOME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Herriot Tabuteau, M.D.”): 33,257,792 for, 526,545 withheld, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class III directors until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 78 asset managers voting on “Election of Directors: Herriot Tabuteau, M.D.” at AXSOME THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,358,5900 00For
Invesco484,7960 00For
Delaware/Macquarie466,3230 00For
MUTUAL FUND SERIES TRUST446,9860 00For
BlackRock408,2300 00For
Charles Schwab302,8490 00For
Waddell & Reed199,2600 00For
Loomis Sayles160,4000 00For
State Street135,9290 098For
JPMorgan132,9030 00For
Putnam100,3000 00For
Fidelity85,2130 00For
Hartford82,7050 00For
Legg Mason73,5000 00For
DWS65,2630 00For
First Trust52,4840 00For
Equitable49,4330 00For
Northwestern Mutual48,6890 00For
Neuberger Berman45,5280 00For
TIAA43,6020 00For
DRIEHAUS MUTUAL FUNDS43,2970 00For
Allspring41,0590 00For
MoA Funds Corp41,0050 00For
Lincoln Financial40,2270 00For
CARILLON SERIES TRUST32,4940 00For

Fund voting reports, all 78 managers: 7,298,109 for, 19,350 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 2 asset managers voting on “Election of Directors: Herriot Tabuteau, M.D.” at AXSOME THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Altium Capital Management LP120,0000 00For
Keel Point, LLC670 00For

Institutional-manager reports, all 2 managers: 120,067 for.

Elect Director: Mark Coleman, M.D.

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD
FOR: 27,121,859WITHHELD: 6,662,478
Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: Election of Directors: Mark Coleman, M.D.

AXSOME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mark Coleman, M.D.”): 27,121,859 for, 6,662,478 withheld, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class III directors until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified.”
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 78 asset managers voting on “Election of Directors: Mark Coleman, M.D.” at AXSOME THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,358,5900 00For
Invesco00 0484,796Withhold
Delaware/Macquarie00 0466,323Withhold
MUTUAL FUND SERIES TRUST414,4860 00For
BlackRock408,2300 00For
Charles Schwab00 0302,849Withhold
Waddell & Reed00 0199,260Withhold
Loomis Sayles00 160,4000Abstain
State Street2890 0135,738Withhold
JPMorgan132,9030 00For
Putnam100,3000 00For
Fidelity85,2130 00For
Hartford82,7050 00For
Legg Mason73,5000 00For
DWS00 065,263Withhold
First Trust00 052,484Withhold
Equitable9,3530 040,080Mixed
Northwestern Mutual48,6890 00For
Neuberger Berman45,5280 00For
TIAA00 043,602Withhold
DRIEHAUS MUTUAL FUNDS00 043,297Withhold
Allspring00 041,059Withhold
MoA Funds Corp00 041,005Withhold
Lincoln Financial10,5270 029,700Mixed
CARILLON SERIES TRUST00 32,4940Abstain

Fund voting reports, all 78 managers: 4,878,217 for, 2,184,068 withheld, 222,674 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 2 asset managers voting on “Election of Directors: Mark Coleman, M.D.” at AXSOME THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Altium Capital Management LP120,0000 00For
Keel Point, LLC067 00Against

Institutional-manager reports, all 2 managers: 120,000 for, 67 against.

Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 12 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 32,850,943AGAINST: 866,046

Prior year: 97.7% for (June 2, 2023 meeting) ▼ 0.3 pts

Details: description as filed, official tally, votes by 262 asset managers

Description as filed by funds: To approve, by non-binding advisory vote, the compensation of our named executive officers.

AXSOME THERAPEUTICS INC.’s own tally for this item (“3. Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers”): 32,850,943 for, 866,046 against — passed, per its Form 8-K filed June 11, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders voted to approve, by non-binding advisory vote, the compensation of the Company's named executive officers.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 79 asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers.” at AXSOME THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,358,5900 00For
Invesco388,90395,893 00Mixed
Delaware/Macquarie466,3230 00For
MUTUAL FUND SERIES TRUST446,9860 00For
BlackRock408,2300 00For
Charles Schwab302,8490 00For
Waddell & Reed199,2600 00For
Loomis Sayles160,4000 00For
State Street135,94285 00For
JPMorgan132,9030 00For
Putnam100,3000 00For
Fidelity85,2130 00For
Hartford82,7050 00For
Legg Mason73,5000 00For
DWS65,2630 00For
First Trust52,4840 00For
Equitable49,4330 00For
Northwestern Mutual48,6890 00For
Neuberger Berman45,5280 00For
TIAA43,6020 00For
DRIEHAUS MUTUAL FUNDS43,2970 00For
Allspring41,0590 00For
MoA Funds Corp41,0050 00For
Lincoln Financial40,2270 00For
CARILLON SERIES TRUST32,4940 00For

Fund voting reports, all 79 managers: 7,221,746 for, 99,955 against, 3,039 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 204 asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers.” at AXSOME THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fairmount Funds Management LLC2,360,0770 00For
RTW INVESTMENTS, LP2,269,6180 00For
Putnam1,043,2500 00For
RA CAPITAL MANAGEMENT, L.P.1,000,0000 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST795,3720 00For
State Street781,391163 00For
BlackRock770,9384,074 00For
Deep Track Capital, LP770,4360 00For
Invesco404,420109,525 00Mixed
ADAGE CAPITAL PARTNERS GP, L.L.C.471,9540 00For
Wellington447,0390 00For
PNC BANK, NATIONAL ASSOCIATION394,9950 00For
Avidity Partners Management LP365,7750 00For
Fidelity317,2200 00For
Charles Schwab302,8500 00For
Point72297,3380 00For
PICTET ASSET MANAGEMENT SA254,5350 00For
Loomis Sayles242,4050 00For
Hood River Capital Management LLC215,0970 00For
Northern Trust208,81925 00For
JPMorgan196,6770 00For
EAGLE ASSET MANAGEMENT INC167,6610 00For
Cormorant Asset Management, LP155,7340 00For
Citadel139,3390 00For
US BANK NATIONAL ASSOCIATION132,3070 00For

Institutional-manager reports, all 204 managers: 16,707,656 for, 390,686 against, 4,000 withheld, 803 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Deloitte & Touche LLP

Official resultFund totals may overlapAUDIT-RELATEDReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

99.6% Approved · of votes cast

FOR 99.6%
FOR: 39,146,384AGAINST: 153,117
Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

AXSOME THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Appointment of Deloitte & Touche LLP”): 39,146,384 for, 153,117 against — passed, per its Form 8-K filed June 11, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 77 asset managers voting on “To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting f” at AXSOME THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,358,5900 00For
Invesco484,7960 00For
Delaware/Macquarie466,3230 00For
MUTUAL FUND SERIES TRUST446,9860 00For
BlackRock408,2300 00For
Charles Schwab302,8490 00For
Waddell & Reed199,2600 00For
Loomis Sayles160,4000 00For
State Street136,0270 00For
JPMorgan132,9030 00For
Putnam100,3000 00For
Fidelity85,2130 00For
Hartford82,7050 00For
Legg Mason73,5000 00For
DWS65,2630 00For
First Trust52,4840 00For
Equitable49,4330 00For
Northwestern Mutual48,6890 00For
Neuberger Berman45,5280 00For
TIAA43,6020 00For
DRIEHAUS MUTUAL FUNDS43,2970 00For
Allspring41,0590 00For
MoA Funds Corp41,0050 00For
Lincoln Financial40,2270 00For
CARILLON SERIES TRUST32,4940 00For

Fund voting reports, all 77 managers: 7,301,058 for, 12,523 against, 3,039 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting f” at AXSOME THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Altium Capital Management LP120,0000 00For
HOWLAND CAPITAL MANAGEMENT LLC1,3800 00For
Keel Point, LLC670 00For

Institutional-manager reports, all 3 managers: 121,447 for.

Largest AXSOME THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 47,464,575 shares outstanding at the time of that meeting.

Fund voting reports: top AXSOME THERAPEUTICS INC. shareholders by shares voted on “To approve, by non-binding advisory vote, the compensation of our named executive officers.”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 7.08%
2Invesco 1.02%
3Delaware/Macquarie 0.98%
4MUTUAL FUND SERIES TRUST 0.94%
5BlackRock 0.86%
6Charles Schwab 0.64%
7Waddell & Reed 0.42%
8Loomis Sayles 0.34%
9State Street 0.29%
10JPMorgan 0.28%
Institutional-manager reports: top AXSOME THERAPEUTICS INC. shareholders by shares voted on “To approve, by non-binding advisory vote, the compensation of our named executive officers.”, 2023-2024
#Asset manager % of shares outstanding
1Fairmount Funds Management LLC 4.97%
2RTW INVESTMENTS, LP 4.78%
3Putnam 2.20%
4RA CAPITAL MANAGEMENT, L.P. 2.11%
5MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST 1.68%
6State Street 1.65%
7BlackRock 1.63%
8Deep Track Capital, LP 1.62%
9Invesco 1.08%
10ADAGE CAPITAL PARTNERS GP, L.L.C. 0.99%

Reported AXSOME THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

AXSOME THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Herriot Tabuteau, M.D.9,167,396 19.31%Proxy statement (DEF 14A), proxy filed April 26, 2024
Antecip Capital LLC7,344,500 15.47%Proxy statement (DEF 14A), proxy filed April 26, 2024
RTW Investments, LP4,489,596 9.46%Proxy statement (DEF 14A), proxy filed April 26, 2024
Vanguard Group4,180,646 8.81%Form 13F, quarter ended March 31, 2024
BlackRock3,790,929 7.99%Form 13F, quarter ended March 31, 2024
Citadel Advisors1,302,744 2.74%Form 13F, quarter ended March 31, 2024
State Street938,716 1.98%Form 13F, quarter ended March 31, 2024
FMR (Fidelity)927,883 1.95%Form 13F, quarter ended March 31, 2024
Geode Capital845,407 1.78%Form 13F, quarter ended March 31, 2024
Millennium Management753,618 1.59%Form 13F, quarter ended March 31, 2024

Percentages above are of 47,464,575 shares outstanding, as reported by AXSOME THERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At AXSOME THERAPEUTICS INC.'s shareholder meeting held June 7, 2024, in the 2023-2024 proxy season, 264 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,154 separate fund positions. On the most widely held item on that ballot — To approve, by non-binding advisory vote, the compensation of our named executive officers. — AXSOME THERAPEUTICS INC.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: AXSOME THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 11, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AXSOME THERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

AXSOME THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “AXSOME THERAPEUTICS (AXSM) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/axsome-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.